• CRISPR Therapeutics granted Chief Medical Officer Naimish Patel 24,000 stock options on October 26, 2026.
• Patel also received 12,000 restricted stock units on the same date.
• The stock options expire on October 26, 2036.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CRISPR Therapeutics AG published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-436436), on October 28, 2026, and is solely responsible for the information contained therein.